Format

Send to

Choose Destination
Cytometry B Clin Cytom. 2019 Jul;96(4):294-299. doi: 10.1002/cyto.b.21764. Epub 2019 Feb 3.

Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia.

Author information

1
Hematology Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy.
2
Hematology Unit, University of Siena and Azienda Ospedaliera Universitaria Senese, Siena, Italy.
3
Department of Medical Biotechnologies, University of Siena, Siena, Italy.
4
Division of Hematology, Ospedale S. Eugenio, Rome, Italy.
5
Hematology Division, Foundation IRCCS Ca' Granda-Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
6
Hematology Unit, Careggi University Hospital (AOUC) Firenze, Florence, Italy.
7
Department of Hematology, Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
8
Hematology Division, Azienda Ospedaliera Città della Salute e della Scienza, Torino, Turin, Italy.
9
Università Cattolica del Sacro Cuore Sede di Roma, Rome, Italy.
10
Hematology, Cardarelli Hospital Napoli, Naples, Italy.
11
Hematology Federico II University, Naples, Italy.
12
Hematology Unit, Department of Medical Sciences, University of Cagliari, Cagliari, Italy.
13
Azienda USL Toscana Centro, Ospedale San Giovanni di Dio, Florence, Italy.
14
Division of Hematology, Casa Sollievo Sofferenza, San Giovanni Rotondo, Italy.
15
Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.
16
Hematology Unit, AOU G. Martino, Messina, Italy.
17
Hematology Unit, Ospedale Oncologico A. Businco, Cagliari, Italy.
18
Azienda Ospedaliera S. Maria, Division of Onco-Hematology, Terni, Italy.

Abstract

BACKGROUND:

Recent investigations in chronic myeloid leukemia (CML) have focused on the identification and characterization of leukemic stem cells (LSCs). These cells reside within the CD34+ /CD38 /Lin fraction and score positive for CD26 (dipeptidylpeptidase IV) a marker, expressed in both bone marrow (BM) and peripheral blood (PB) samples, that discriminates CML cells from normal hematopoietic stem cells (HSCs) or from LSCs of other myeloid neoplasms. CD26 evaluation could be a useful tool to improve the identification of CML LCSs by using flow-cytometry assay.

METHODS:

CD26+ LSCs have been isolated from EDTA PB and BM samples of patients with leucocytosis suspected for CML. Analysis of LSCs CML has been performed by using custom-made lyophilized pre-titrated antibody mixture test and control tube and a CD45+ /CD34+ /CD38- /CD26+ panel as a strict flow cytometric gating strategy.

RESULTS:

The expression of CD26 on CD34+ /CD38- population was detectable in 211/211 PB and 84/84 BM samples of subsequently confirmed BCR-ABL+ CP-CML patients. None of the 32 samples suspicious for CML but scoring negative for circulating CD26+ LSCs were diagnosed as CML after conventional cytogenetic and molecular testing. To validate our results, we checked for PB CD26+ LSCs in patients affected by other hematological disorders and they all scored negative for CD26 expression.

CONCLUSIONS:

We propose flow cytometry evaluation of CD26 expression on PB CD34+ /CD38- population as a new rapid, reproducible, and powerful diagnostic tool for the diagnosis of CML. © 2019 The Authors. Cytometry Part B: Clinical Cytometry published by Wiley Periodicals, Inc. on behalf of International Clinical Cytometry Society.

KEYWORDS:

CD26+; chronic myeloid leukemia; diagnosis; flow cytometry; leukemic stem cells; peripheral blood

PMID:
30714299
DOI:
10.1002/cyto.b.21764

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center